MEK2 Research Partners with ADViRNA to Advance RNA-Based Therapies

MEK2 Research has partnered with ADVIRNA to develop experimental siRNA- and ASO-based therapies aimed at silencing or correcting the mutant MEK2 allele. This collaboration brings together ADVIRNA’s expertise in custom oligonucleotide design with MEK2 Research’s mission to advance new treatment options for CFC syndrome.
MEK2 Research Partners with ADViRNA to Advance RNA-Based Therapies

MEK2 Research is excited to announce a new partnership with ADViRNA to advance experimental siRNA- and ASO-based (antisense oligonucleotide) therapeutic strategies aimed at silencing or correcting the expression of the mutant MEK2 allele. As part of this collaboration, ADViRNA will design a panel of oligonucleotides specifically targeting the disease-causing SNP.

The project will be supported by ADViRNA’s experienced scientific team:

  • Alexey Wolfson, PhD, MBA — Chief Executive Officer & Chief Scientific Officer
  • Sean McCauley, PhD — Lead Scientist
  • Kyle Foster, PhD — Scientific Project Manager
  • Nick Rice, PhD — Scientist, Research and Development
  • Hannah McCauley — Senior Research Associate, Director of Corporate Operations
  • Sarah Goudreau — Senior Research Associate